by HTLV | Jul 18, 2026 | Publications
Rev Esp Patol. 2026 Jul 17;59(4):100889. doi: 10.1016/j.patol.2026.100889. Online ahead of print. ABSTRACT Human T-lymphotropic virus type 1 (HTLV-1) is associated with immune dysregulation, opportunistic infections, and, less commonly, lymphoproliferative and...
by HTLV | Jul 17, 2026 | Publications
Int J Gynaecol Obstet. 2026 Jul 17. doi: 10.1002/ijgo.71206. Online ahead of print. ABSTRACT OBJECTIVE: Breast cancer (BC) is the leading cause of cancer-related mortality in women. Atrazine, a prevalent herbicide, is a persistent environmental pollutant with...
by HTLV | Jul 15, 2026 | Publications
Cancers (Basel). 2026 Jun 28;18(13):2101. doi: 10.3390/cancers18132101. ABSTRACT Human T-cell leukemia virus-1 (HTLV-1) is the etiological agent of a series of chronic inflammatory diseases such as HTLV-associated myelopathy/Tropical spastic paraparesis (HAM/TSP),...
by HTLV | Jul 15, 2026 | Publications
Tumour Virus Res. 2026 Jul 14:200347. doi: 10.1016/j.tvr.2026.200347. Online ahead of print. ABSTRACT Human T-cell Leukemia Virus type 1 (HTLV-1) drives Adult T-cell Leukemia/Lymphoma (ATLL) through sustained expression of the viral oncoprotein HBZ. Although HBZ is...
by HTLV | Jul 14, 2026 | Publications
Nucleic Acids Res. 2026 Jul 3;54(13):gkag680. doi: 10.1093/nar/gkag680. ABSTRACT Human T-cell leukemia virus type 1 (HTLV-1), an oncogenic retrovirus, uses human tRNAPro to prime reverse transcription. How tRNAPro is annealed to the primer-binding site (PBS), which is...
by HTLV | Jul 14, 2026 | Publications
BMC Infect Dis. 2026 Jul 13. doi: 10.1186/s12879-026-14010-1. Online ahead of print. ABSTRACT BACKGROUND: This study was designed to determine the seroprevalence of HTLV among multi-transfused patients in the South of Iran. METHODS: All patients with β-thalassemia...
